BACKGROUND: As panel testing becomes more common in clinical practice, it is important to understand the prevalence and trends associated with the pathogenic variants (PVs) identified. This is especially true for genetically heterogeneous cancers, such as breast cancer (BC), in which PVs in different genes may be associated with various risks and cancer subtypes. The authors evaluated the outcomes of genetic testing among women who had a personal history of BC. METHODS: A total of 35,409 women with a single diagnosis of BC who underwent clinical genetic testing with a 25-gene panel were included in the current analysis. Women with multiple BCs and men with BC were excluded. The frequency and distribution of PVs were assessed for the overall cohort, among women with triple-negative BC (TNBC) (n 5 4797), and by age at diagnosis. RESULTS: PVs were identified in 9.3% of women tested; 51.5% of PVs were identified in genes other than breast cancer 1 (BRCA1) and BRCA2, including checkpoint kinase 2 (CHEK2) (11.7%), ataxia telangiectasia mutated (ATM; ATM serine/threonine kinase) (9.7%), and partner and localizer of BRCA2 (PALB2) (9.3%). The prevalence of PVs in BRCA1, PALB2, BRCA1-associated RING domain 1 (BARD1), BRCA1-interacting protein C-terminal helicase 1 (BRIP1), and RAD51 paralog C (RAD51C) was statistically higher among women with TNBC. The PV rate was higher among women aged <40 years, lower among women aged >59 years, and relatively constant (8.5%-9.0%) among women who were diagnosed between ages 40 and 59 years. CONCLUSIONS: These results demonstrate that panel testing increased the number of women identified as carrying a PV in this cohort compared with BRCA testing alone. Furthermore, the proportion of women identified who carried a PV in this cohort did not decrease between ages 40 and 59 years.
INTRODUCTION
Historically, the risk of hereditary breast and ovarian cancer (HBOC) has been linked to pathogenic variants (PVs) in breast cancer 1 (BRCA1) and BRCA2. PVs in these 2 genes are associated with a lifetime risk of breast cancer between 41% and 90%. [1] [2] [3] However, it is now estimated that more than one-half of individuals with a PV who meet the National Comprehensive Cancer Network (NCCN) testing criteria for HBOC carry PVs in genes other than BRCA1 or BRCA2. 4 Breast cancer is also a component of several other well described cancer syndromes, including Li-Fraumeni syndrome, Cowden syndrome, Peutz-Jeghers syndrome, 5, 6 and hereditary diffuse gastric cancer. Thus, it is established that women who carry PVs in tumor protein p53 (TP53), 7 phosphatase and tensin homolog (PTEN), 6, 8 serine/threonine kinase 11 (STK11), 9 and cadherin 1 (CDH1) 10, 11 have an increased risk of breast cancer. PVs in the ataxia telangiectasia mutated (ATM; ATM serine threonine kinase), 12 checkpoint kinase 2 (CHEK2), 13, 14 and partner and localizer of BRCA2 (PALB2) 15 genes also cause an increased breast cancer risk.
Genetic testing allows patients with an increased risk of cancer to receive appropriate medical management that may reduce risk for themselves and their family members. Early identification of at-risk individuals allows for increased clinical surveillance and may prompt more aggressive prevention strategies, such as prophylactic surgery or chemoprevention. In addition, family members may be at high risk for certain cancers and may be eligible for genetic testing and other medical interventions. With the expansion of the genes known to be associated with an increased risk of breast cancer, NCCN guidelines have also expanded to incorporate these genes into medical management recommendations.
Traditional, single-syndrome genetic testing is reliant on clinical identification of the appropriate hereditary cancer syndrome based on overt personal and/or family history. This can present a significant clinical challenge because of the syndromic overlap between many cancerpredisposition genes. The introduction of next-generation sequencing platforms, which allow the simultaneous sequencing of multiple genes, has increased the number of individuals identified as being at an increased risk for breast cancer. [17] [18] [19] [20] Next-generation sequencing has also introduced new challenges, such as a higher probability of detecting a variant of uncertain significance (VUS) or a PV with limited clinical relevance.
As our understanding of the genetic heterogeneity of breast cancer has grown, evidence that PVs in different genes may be associated with different breast cancer subtypes has emerged. For example, it is well know that PVs in BRCA1 are associated with estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor 2 (HER2)-negative (triple-negative) breast cancer, 17, 21, 22 whereas PVs in TP53 are associated with HER2-positive breast cancer. 23, 24 Evidence is also growing that PVs in genes other than BRCA1 and BRCA2 are associated with earlier onset breast cancer. 20 However, recent data also suggest that the overall positive rate of PVs in genes associated with breast cancer other than BRCA1 and BRCA2 does not depend on age at the time of personal cancer diagnosis. 25 As panel testing is integrated into clinical practice, it is important to understand the prevalence and trends associated with the spectrum of PVs identified in women with breast cancer. This is a vital component in ensuring that medical management and testing guidelines are updated as appropriate. The objective of the current study was to gain a better understanding of the PVs identified in patients with a personal diagnosis of breast cancer who underwent testing with a 25-gene hereditary cancer panel. Triple-negative status and age at diagnosis were also evaluated.
MATERIALS AND METHODS
A retrospective database analysis was performed for individuals who were submitted for genetic testing using a 25-gene hereditary cancer panel (Myriad Genetic Laboratories, Inc, Salt Lake City, Utah) between September 2013 and August 2015. The 25-gene panel includes BRCA1, BRCA2, ATM, adenomatosis polyposis coli (APC), BRCA1-associated RING domain 1 (BARD1), bone morphogenetic protein receptor type 1A (BMPR1A), BRCA1-interacting protein C-terminal helicase 1 (BRIP1), CDH1, cyclin-dependent kinase 4 (CDK4), cyclin-dependent kinase inhibitor 2A (CDKN2A), CHEK2, epithelial cell adhesion molecule (EPCAM), mutL homolog 1 (MLH1), mutS homolog 2 (MSH2), MSH6, mutY DNA glycosylase (MUTYH), nibrin (NBN), PALB2, PMS1 homolog 2 (PMS2), PTEN, RAD51 paralog C (RAD51C), RAD51D, SMAD family member 4 (SMAD4), STK11, and TP53. Sequencing and large rearrangement analyses were performed for all genes on the panel except EPCAM, for which only large rearrangement analysis was performed. PVs are defined as those with a laboratory classification of pathogenic or likely pathogenic. 26, 27 Only biallelic mutations in MUTYH are reported as PVs.
These 25 genes were included on the panel based on their association with 1 or more of the following 8 cancers: breast, ovarian, colon, endometrial, melanoma, pancreatic, gastric, and prostate. The panel genes may also be associated with other cancer risks. The genes on this panel with a known association with breast cancer include BRCA1, BRCA2, ATM, BARD1, BRIP1, CDH1, CHEK2, NBN, PALB2, PTEN, STK11, and TP53.
Individuals were included in this analysis if they were women and had a single personal diagnosis of breast cancer at the time of testing. Women who had more than 1 diagnosis of breast cancer were not included. Only women who were initially submitted for testing with the panel were included. For example, women of Ashkenazi Jewish ancestry who tested negative for 3 common founder mutations in BRCA1 and BRCA2 before going on to panel testing were not included (n 5 949). All patient data regarding clinical history were obtained by health care provider report on test requisition forms (TRFs), on which check boxes are provided to indicate ancestry, personal history of breast cancer, and triple-negative status. Family history is recorded as free text.
Overall, 35,409 women with a single breast cancer diagnosis who were tested with the 25-gene hereditary cancer panel were included in this analysis. These included 32,993 of 35,409 women (93.2%) who met NCCN guidelines for HBOC testing, as defined by the NCCN in 2013. These guidelines included women who had a personal history of breast cancer diagnosed at a young age (45 years) and women diagnosed after age 45 years who had a family history of breast, ovarian, and/or pancreatic cancer. The family history requirements for patients diagnosed between ages 46 and 50 years included 1 or more close relative(s) with breast or pancreatic cancer at of age. Women who were diagnosed with breast cancer after age 50 years meet NCCN guidelines if they had the following Original Article family history: 1 or more close relative(s) with breast cancer diagnosed before age 50 years, invasive ovarian cancer at any age, or male breast cancer at any age; or 2 close relatives with breast or pancreatic cancer at any age. Family history of prostate cancer was excluded because the Gleason score is not typically documented on the TRF. This may have resulted in an underestimate of the number of patients who met HBOC testing criteria.
Descriptive statistics, including frequencies and percentages, were calculated. The distribution and prevalence of PVs (the proportion of individuals with a PV among all tested individuals) were analyzed for the full cohort of women with a single breast cancer diagnosis as well as by subtype. Only the triple-negative subtype was considered here because other subtypes are not reliably captured on the TRF. Fisher exact tests were performed to determine the differences between prevalence rates of genes across triple-negative status and the positive rate by age at diagnosis (in 5-year intervals). False-discovery rate-controlling adjustments were used for multiple comparisons. Adjusted P values < 0.05 were considered statistically significant.
RESULTS
Among the 35,409 women with a single breast cancer diagnosis who were tested using the 25-gene hereditary cancer panel, approximately one-half were of Northern/ Western European ancestry (Table 1) . Other commonly reported ancestries included African (7.1%), Latin American/Caribbean (7.1%), Central/Eastern European (5.3%), and Asian (3.4%). A large proportion of women who underwent testing indicated multiple ancestries (10.2%) or did not specify any ancestry (17.9%) on the TRF. This cohort included 4797 women (13.5%) who were diagnosed with triple-negative breast cancer (TNBC). The only difference in ancestry distribution according to triple-negative status occurred for women of African ancestry. A greater proportion of women with TNBC were of African ancestry (13.0%) relative to women with other subtypes (6.2%) (Supporting Table 1 ; see online supporting information). This is consistent with previous literature in which an enrichment of TNBC was demonstrated among women of African ancestry.
Overall, 3305 of 35,409 women who underwent testing (9.3%) carried at least 1 PV. Among the women who met NCCN testing criteria, 9.6% (316 of 32,993) had a mutation identified, compared with 5.9% (143 of 2416) of those who did not meet NCCN criteria. The positive rate ranged from 7.2% to 11.5% based on ancestry ( Table 1 ). The positive rate among women of Ashkenazi Jewish ancestry tested in this cohort was 8.4%, which was lower than that in previous reports. 28, 29 This was likely because women who were tested first for the 3 common founder mutations in BRCA1 and BRCA2 were not included in the current study. Among all women tested, 36.7% had at least 1 VUS identified.
Distribution of PVs
Nearly one-half of the PVs identified during testing were in the BRCA1 (24.0%) and BRCA2 (24.4%) genes, as indicated in Table 2 . An additional 40.9% of the PVs identified were in other genes associated with breast cancer, including CHEK2 (11.7%), ATM (9.7%), and PALB2 (9.3%). Other genes on the panel accounted for 10.7% of mutations, including those associated with Lynch syndrome (7.0%). No mutations were identified in CDK4 or BMPR1A.
Among women with TNBC, 674 of 4797 (14.1%) were found to carry a PV, which is consistent with previous reports. 17 The distribution of PVs shifted when triple-negative status was considered, with one-half of all PVs among women with TNBC occurring in the BRCA1 gene alone (Table 2 ). In total, BRCA1 and BRCA2 accounted for 68.2% of the PVs identified in women with TNBC. Other genes associated with breast cancer accounted for 21.8% of PVs, with the largest contribution from PALB2 (8.7%).
The positive rate among women with subtypes of breast cancer other than TNBC was 8.6% (2631 of 30,612 women). Among these women, BRCA1 and BRCA2 accounted for 43.4% of the PVs identified ( Table  2 ). The proportion of BRCA1 mutations was much lower in other breast cancer subtypes (17.3%), as expected. Other genes associated with breast cancer accounted for 45.7% of PVs in this population, which was about the same as the percentage for BRCA1 and BRCA2. 
Mutation Prevalence
The prevalence of PVs in the overall population of women who had a single diagnosis of breast cancer and underwent testing with the 25-gene panel is illustrated in Figure 1A .
The prevalence of PVs in BRCA1 and in BRCA2 was nearly equal at about 2.3% each. Overall, 51.5% of mutations were identified in genes other than BRCA1 and BRCA2 (Fig. 1A, inset) . The prevalence of PVs in other genes associated with breast cancer was nearly 4%. These included a prevalence of PVs in ATM, CHEK2, and PALB2 of approximately 1% each. The prevalence of PVs in the remaining breast cancer genes ranged from 0.05% to 0.31%. There was a marked shift in the gene-specific mutation prevalences in this population when triple-negative status was taken into account (Fig. 1B) . The prevalence of PVs in BRCA1 was 7.2% among women who had TNBC compared to only 1.5% among those who had other breast cancer subtypes. This indicates that the women tested here were much more likely to carry a PV in BRCA1 if they had TNBC (P < .001). However, the prevalence of PVs in BRCA2 was similar in women with TNBC and those with other breast cancer subtypes (2.6% vs 2.3%; P 5 .415). This indicates that triple-negative status did not significantly impact the likelihood of carrying a mutation in BRCA2 among the women included in this analysis.
The overall prevalence of PVs in other genes associated with breast cancer was only slightly lower among women who had TNBC (3.1%) compared with those who had other breast cancer subtypes (4.0%), as illustrated in Figure 1B . Although women with TNBC had a lower prevalence of PVs in other breast cancer genes, the difference was far less than that observed for PVs in BRCA1. This suggests that the high proportion of BRCA1 mutations identified in women with TNBC did not result in an equivalent decrease in the likelihood of carrying a mutation in another gene associated with breast cancer.
Although the overall prevalence of PVs in other genes associated with breast cancer was similar, triplenegative status appeared to have a significant impact on the prevalence of individual genes. The prevalence of PVs in some genes associated with breast cancer was statistically different according to triple-negative status, as illustrated in Figure 1B . PVs in PALB2 (1.3% vs 0.8%; P 5 .021), BARD1 (0.5% vs 0.1%; P < .001), and BRIP1 (0.6% vs 0.3%; P 5 .001) were enriched in women who had TNBC compared with those who had other breast cancer subtypes. Meanwhile, PVs in CHEK2 (0.2% vs 1.3%; P < .001) and ATM (0.3% vs 1.0%; P < .001) were enriched in women who had other breast cancer subtypes. The prevalence of PVs in the remaining genes associated with breast cancer (NBN, PTEN, STK11 , and TP53) did not differ statistically according to triplenegative status.
The overall prevalence of PVs in other genes on the panel that were not associated with breast cancer was very similar for women with TNBC (1.4%) and those with other breast cancer subtypes (1.0%) (Fig. 1B) . The prevalence of PVs in all individual genes was also similar regardless of subtype, with the exception of RAD51C, which was significantly enriched in women with TNBC (0.4% vs 0.1%; P < .001).
Age at Diagnosis
The majority of women were diagnosed between ages 35 and 59 years (Supporting Table 2 ; see online supporting information). The PV-positive rate for all women with breast cancer according to age at diagnosis is illustrated in Figure  2A . As expected, the positive rate among women who were diagnosed before age 40 years was much higher than the average positive rate (9.3%) and ranged from 13% to 18%. Women who were diagnosed between ages 40 and 44 years and between ages 45 and 49 years had a PV-positive rate of 9.0% and 8.6%, respectively. Relative to women who were diagnosed between ages 45 to 49 years, there was no statistical difference in the positive rate among women who were diagnosed between ages 50 and 54 years (8.5%; P 5 .867) and between ages 55 and 59 years (9.0%; P 5 .477) ( Fig.  2A) . The positive rate among women who were diagnosed after age 60 years decreased with increasing age, from 7.6% among women who were diagnosed between ages 60 and 64 years to 4.3% among those who were diagnosed between ages 85 and 89 years ( Fig. 2A) . When triple-negative status is taken into account, women with TNBC who were diagnosed before age 40 years had a higher PV-positive rate than those with other subtypes, ranging from 22.5% to 29.1%. Women who were diagnosed with TNBC between ages 40 and 59 years had a decreasing positive rate with age; however, women who were diagnosed between ages 55 and 59 years still had a positive rate of 9.6%. Women with TNBC who were diagnosed after age 60 years had a wide range of positive rates, from 0% to 16.7%. This is an artifact of the Figure 1 . The prevalence of pathogenic variants (PVs) is illustrated according to gene type for (A) all individuals with breast cancer and (B) those with triple-negative status. APC indicates adenomatosis polyposis coli; ATM, ataxia telangiectasia mutated (ATM serine/threonine kinase); BARD1, BRCA1-associated RING domain 1); BRCA1, breast cancer 1; BRCA2, breast cancer type 2; BRIP1, BRCA1-interacting protein C-terminal helicase 1; CDH1, cadherin 1; CDKN2A, cyclin-dependent kinase inhibitor 2A; CHEK2, checkpoint kinase 2; EPCAM, epithelial cell adhesion molecule; MLH1, mutL homolog 1; MSH2, mutS homolog 2; MSH6, mutS homolog 6; MUTYH, mutY DNA glycosylase; NBN, nibrin; PALB2, partner and localizer of BRCA2; PMS2, PMS1 homolog 2; PTEN, phosphatase and tensin homolog; RAD51C, RAD51 paralog C; RAD51D, RAD paralog D; SMAD4, SMAD family member 4; STK11, serine/threonine kinase 11; TNBC, triple-negative breast cancer; TP53, tumor protein p53.
small number of women with TNBC who were tested in these age groups.
Among women with other breast cancer subtypes who were diagnosed before age 40 years, the positive rate was lower than that observed for women with TNBC and ranged from 12.1% to 16.3%. Women who were diagnosed between ages 40 and 59 years exhibited a trend similar to that observed in the overall cohort, with a fairly consistent positive rate of approximately 8%. Women who were diagnosed with other breast cancer subtypes after age 60 years also had a decreasing positive rate with increasing age, dropping to 3.4% among those diagnosed between ages 85 and 89 years.
The positive mutation rate was also assessed by age for the different genes in the panel. Women who were diagnosed before age 40 years had a much higher positive rate for PVs in BRCA1 and BRCA2 (range, 7.9%-13.8%) than other genes associated with breast cancer (range, 3.6%-7.7%), as illustrated in Figure 3 . Among women who were diagnosed between ages 40 and 59 years, the positive rate for PVs in BRCA1 and BRCA2 (range, 3.7%-4.7%) and in other breast cancer genes (range, 3.5%-4.5%) was about equal. After age 60 years, the positive rates for PVs in other breast cancer genes were slightly higher than or equal to the positive rates for BRCA1 and BRCA2.
DISCUSSION
The analysis presented here demonstrates the distribution and prevalence of PVs in >35,000 women who were Figure 2 . The prevalence of pathogenic variants is stratified by age (A) in all individuals with breast cancer and (B) according to triple-negative breast cancer (TNBC) status. Women who were missing information for age at diagnosis were not included.
diagnosed with breast cancer and underwent testing with a 25-gene hereditary cancer panel. To the best of our knowledge, this represents the largest study of its kind to date. These results support other recent studies indicating that panel testing can identify larger numbers of women who are at increased risk for breast cancer compared with BRCA testing alone. [17] [18] [19] [20] 25, 30, 31 Overall, 9.3% of the women tested were identified as carrying a PV, where >50% of PVs were in genes other than BRCA1 and BRCA2. This includes a substantial proportion of PVs in other genes associated with breast cancer, with the largest contributions from ATM, CHEK2, and PALB2. This supports other recent literature indicating that PVs in these 3 genes are associated with an increased risk of breast cancer [12] [13] [14] [15] sufficient to justify altered medical management according to NCCN guidelines, although the degree of increased risk is less clearly defined than for BRCA1 and BRCA2.
In addition, these findings highlight that gene panels are increasingly relevant in oncology, as syndromic overlap among many cancer-risk genes may prevent clinicians from effectively using family history alone to identify appropriate single-syndrome testing. For example, there is no evidence that the clinical presentation of women with PVs in PALB2 would be any different from women with PVs in BRCA1 or BRCA2. Therefore, many women with non-BRCA mutations may not be identified as candidates for increased breast screening using traditional singlesyndrome testing. In addition, NCCN guidelines have been expanded and updated to incorporate many of the non-BRCA genes that are included on this panel. This provides clinicians with gene-specific guidelines for medical management. For example, women identified as carrying PVs in genes such as BRIP1 and RAD51C are now recommended to consider salpingo-oophorectomy. 16 Women with PVs in other genes, such as ATM, CHEK2, and PALB2, are candidates for increased breast screening.
The inclusion of additional genes in the 25-gene panel that have not traditionally been included in singlesyndrome testing resulted in a VUS rate of 36.7%. This is consistent with other reports of panel testing for hereditary cancer risk, which ranged from approximately 30% to 40%. 25, 32, 33 This VUS rate is expected to decrease with continued testing, as observed previously with BRCA1 and BRCA2 single-syndrome testing. 26 Although there are conflicting reports in the literature regarding the clinical impact on patient management and anxiety, [34] [35] [36] [37] professional society guidelines recommend that individuals with a VUS should be managed based on personal and family cancer history. 16 Consistent with previous studies, the prevalence of BRCA1 PVs was greatly enriched in women with TNBC. 17, 38 However, significant differences were also observed in the prevalence of PVs in most of the other genes associated with breast cancer (ATM, BARD1, BRIP1, CHEK2, and PALB2) as well as RAD51C. These findings may suggest that differences in gene-based TNBC risk should be considered during medical management decisions. The difference in mutation prevalence based on triple-negative status may also suggest different gene pathways for disease development, which may impact disease treatment. This is consistent with previous studies that demonstrated sensitivity to DNA-damaging agents, such as platinum-containing regimens, among women with TNBC. 39, 40 The impact of age at diagnosis on the PV-positive rate was also evaluated. Among the women tested here, the positive rate did not drop below 8.5% until after age 60 years. Notably, there was no statistical difference in the positive rate among women diagnosed between ages 50 and 59 years relative to those diagnosed between ages 45 and 49 years. This is of particular interest because current NCCN guidelines state that women with a personal cancer diagnosis before age 45 years (or age 50 years with some family history of breast cancer) should be recommended for genetic testing. The data shown here suggest that there may not be a decrease in mutation prevalence between ages 45 and 59 years. Since most women who were included in this study met NCCN testing criteria, in part because of family cancer history, additional studies that account for family history are needed to further investigate this possibility.
The trends observed in the overall population persisted when triple-negative status was taken into account. Although the positive rate was higher among women with TNBC at all ages, the positive rate did not decrease in women who were diagnosed with other breast cancer subtypes between ages 40 and 59 years. This suggests that the persistence of the PV-positive rate is not an artifact of including women with TNBC, who are known to have higher positive rates relative to those with other subtypes. Although women aged > 45 years likely had additional family cancer history, these results are consistent with a recent study in an unselected cohort of women with breast cancer. 25 The positive rate according to age at diagnosis was also computed according to the gene type. This demonstrated that women who were diagnosed before age 40 years had a higher positive rate in BRCA1 or BRCA2 than in other genes associated with breast cancer. However, women who were diagnosed between ages 40 and 59 years had similar positive rates in BRCA1/BRCA2 or other breast cancer genes, suggesting that the inclusion of these additional genes on the panel may identify women who are at increased risk for breast cancer.
Although the majority of PVs were identified in genes associated with breast cancer, a positive rate of about 1% was observed for other genes on the panel and exhibited no apparent trend with age. These findings may be consistent with family history of cancers not associated with HBOC. It is also possible that these are incidental findings of PVs in genes that may not be apparent in the family history based on gene prevalence, family size, or paternal lineage. However, the PVs identified in genes associated with Lynch syndrome and colorectal cancer, among others, represent clinically actionable findings identified by testing with a pan-cancer panel.
Tung et al previously evaluated the use of a 25-gene panel in a consecutive series of women with breast cancer who received treatment at a large academic institution. 25 In their study, 10.7% of women tested had a PV identified, with a positive rate of 7.5% among women who were diagnosed between ages 46 and 60 years. The positive rate in this age group is slightly lower than that observed in our current study (range, 8.5%-9.0%), which likely reflects the use of an unselected cohort by Tung and colleagues. Given the limited size of that study (n 5 488), the evaluation of age at diagnosis was limited to 15-year intervals. The large size of our current cohort enabled us to evaluate age in 5-year intervals, demonstrating not only that the positive PV rate is high in this age group but also that it remains constant from ages 45 to 60 years. Thompson et al assessed a panel of 18 genes with known or proposed breast cancer risk in a high-risk cohort of women who had a personal and family history of breast cancer and previously tested negative for mutations in BRCA1 and BRCA2. 30 The studies by both Tung et al and Thompson et al demonstrated that 4% to 5% of tested women carried a mutation in a non-BRCA cancer-predisposition gene, which is consistent with our finding that 4.9% of tested women had a PV identified in a gene other than BRCA1 or BRCA2. However, both of those previous studies were underpowered to evaluate trends associated with high-penetrance (but rare) PVs in genes such as CDH1 and STK11. Here, PVs were observed in a total of 23 unique genes, providing a more thorough evaluation of panel testing.
There were limitations to this analysis. Clinical information, including personal and family cancer history, were collected on the TRF. As such, triple-negative status was not separately confirmed with pathology. This may have resulted in an over-or under-estimation of the proportion of women with TNBC in the cohort. In addition, women of Ashkenazi Jewish ancestry were excluded from the analysis if they had previously been tested for the 3 founder mutations in BRCA1 and BRCA2. Although this was done to minimize convolution of the BRCA1 and BRCA2 PVs identified by the panel test, it likely dilutes the positive rate within this ancestry. The majority of women included in this analysis met testing criteria for HBOC. Thus, women aged > 45 years who were diagnosed with a non-triple negative breast cancer would have Original Article required additional family cancer history to meet testing criteria.
The identification of a PV in a cancer-susceptibility gene allows for increased clinical surveillance and early detection of second cancers, and it may prompt more aggressive prevention strategies in both patients and family members. Relative to testing for only BRCA1 and BRCA2, panel testing more than doubled the number of women identified here as candidates for modified medical management, although the degree of increased risk and the appropriate medical management were not clear for carriers of PVs in several of the genes included on the panel. In addition, our results demonstrate that the positive rate does not change appreciably between ages of 40 and 59 years. These findings are also consistent with a recently published study in an unselected cohort. 25 Additional research in women diagnosed with breast cancer after age 45 years may further elucidate the association of family cancer history with a positive PV rate in this group.
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